Previous close | 0.8500 |
Open | 0.8500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.00 |
Expiry date | 2024-12-20 |
Day's range | 0.8500 - 0.8500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website. Jefferies Global Healthcare Conference in New York on June 5, 2024, at 4:30 p.m. ET. Goldman Sachs Healthcare Conference in Miami Beach on June 12, 2024, at 8:40 a.m. ET. Live webcasts can be accessed on the investor and media section of the Esperi
– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments to Reduce Cardiovascular Risk by Lowering Low-Density Lipoprotein Cholesterol (LDL-C) Levels – – This Makes Bempedoic Acid the First and Only LDL-C Lowering Treatment Indicated for Primary and Secondary Prevention of Cardiovascular Events – – Up To 80% Of Patients Do Not Reach Guideline-Recommended L